CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Response to Letter]

Abstract

Sheng-jun Wang, Xue-wu Liu Department of Neurology, Qilu Hospital, Shandong University, Ji’nan, People’s Republic of ChinaCorrespondence: Sheng-jun Wang; Xue-wu LiuDepartment of Neurology, Qilu Hospital, Shandong University, 107# Wen Hua Xi Road, Ji’nan 250012, People’s Republic of ChinaEmail [email protected]; [email protected] for the concerns and comments of Mr. Zuowei Duan. There were indeed some limitations in our published article since it was only a preliminary exploratory research. As for the rarity of LGI1 encephalitis, only sixteen patients were enrolled in our study. The multifactorial analysis of variance was hard to be evaluated. But we do believe the statistical significance of our finding about the increasing of CXCL13 levels in the patients.We agree that the clinical significance of CXCL13 levels increasing should not be over-estimated by clinicians. We have stated that the increasing of CXCL13 levels were reported in other autoimmune diseases including multiple sclerosis, neuroborreliosis and anti-NMDAR encephalitis in “Discussion Section” of our published article. The specificity and sensitivity of CXCL13 in serum/CSF for autoimmune encephalitis still need to be further investigated. Anyhow, we have found a potential biomarker for the diagnosis of anti-LGI1 encephalitis.This is in response to the Letter to the Editor View the original paper by Lin and colleagues.